Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2012. The report details a specific share repurchase transaction executed on March 8, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 500,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,422.5 pence per share; lowest price paid was 1,409 pence per share.
- Treasury Holdings: Post-transaction, the Company holds 510,497,927 shares in Treasury (9.19% of total issued share capital).
- Total Voting Rights: Including unsettled purchases, Treasury holdings represent 10.15% of total voting rights.
- Shares in Issue: 5,046,712,302 shares (excluding Treasury shares).
Material Changes
The filing does not provide comparative financial data or material changes regarding operational performance versus prior periods. The primary change reported is the reduction of outstanding shares through the repurchase of 500,000 shares and the subsequent increase in Treasury stock holdings.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (510,497,927) against the latest quarterly or annual reports.
- Confirm the calculation of total voting rights (10.15% held in Treasury) for disclosure threshold assessments.
- Check the price paid per share (1,409 to 1,422.5 pence) against market trading data for March 8, 2012.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive metrics.